Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

GeneBits: ultra-sensitive tumour-informed ctDNA monitoring of treatment response and relapse in cancer patients.

Journal of translational medicine - 27 Aug 2025

Broche Julian, Kelemen Olga, Sekar Aishwarya, Schütz Leon, Muyas Francesc, Forschner Andrea, Schroeder Christopher, Ossowski Stephan

Abstract excerpt

BACKGROUND: Circulating tumour DNA (ctDNA) in liquid biopsies has emerged as a powerful biomarker in cancer patients. Its relative abundance in cell-free DNA serves as a proxy for the overall tumour burden. Here we present GeneBits, a method for cancer therapy monitoring and relapse detection. GeneBits employs tumour-informed enrichment panels targeting 20-100 somatic single-nucleotide variants (SNVs) in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Circulating Tumor DNA
Share to High-Throughput Nucleotide Sequencing

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Liquid Biopsy

Share to Neoplasm Recurrence, Local

Share to Neoplasms

Share to Polymorphism, Single Nucleotide

Share to Recurrence

Share to Treatment Outcome

Source

Open in PubMed Open full text

Identifiers

PMID: 40866952
DOI: 10.1186/s12967-025-06993-3
PMCID: PMC12382282

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

GeneBits: ultra-sensitive tumour-informed ctDNA monitoring of treatment response and relapse in cancer patients.PMID 40866952Read ↗

Whole genome error-corrected sequencing for sensitive circulating tumor DNA cancer monitoringSemantic proximity Read ↗

In-depth assessment of BRAF, NRAS, KRAS, EGFR, and PIK3CA mutations on cell-free DNA in the blood of melanoma patients receiving immune checkpoint inhibitionSemantic proximity Read ↗

Analytical and Clinical Validation of Cell-Free Circulating Tumor DNA Assay for the Estimation of Tumor Mutational Burden.Semantic proximity Read ↗

Ultrasensitive plasma-based monitoring of tumor burden using machine-learning-guided signal enrichment.Semantic proximity Read ↗

Machine learning guided signal enrichment for ultrasensitive plasma tumor burden monitoringSemantic proximity Read ↗

Paired plus-minus sequencing is an ultra-high throughput and accurate method for dual strand sequencing of DNA moleculesSemantic proximity Read ↗

Comprehensive benchmarking of methods for mutation calling in circulating tumor DNASemantic proximity Read ↗

Benchmarking of duplex sequencing approaches to reveal somatic mutation landscapesSemantic proximity Read ↗

Implementation of an ISO 15189 accredited next generation sequencing service for cell-free total nucleic acid (cfTNA) analysis to facilitate driver mutation reporting in blood: the experience of a clinical diagnostic laboratorySemantic proximity Read ↗

Comprehensive benchmarking of methods for mutation calling in circulating tumor DNA.Semantic proximity Read ↗

Circulating cell-free messenger RNA enables non-invasive pan-tumour monitoring of melanoma therapy independent of the mutational genotype.Semantic proximity Read ↗

Ultra-deep sequencing data from a liquid biopsy proficiency study demonstrating analytic validity.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.